FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993014774> ?p ?o ?g. }

• W1993014774 endingPage "S11" @default.
• W1993014774 startingPage "S4" @default.
• W1993014774 abstract "Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin, empagliflozin) are new glucose-lowering agents that exert their therapeutic activity independently of insulin by facilitating glucose excretion through the kidneys. However, this simple renal mechanism that results in sustained glucose urinary loss leads to more complex indirect metabolic effects. First, by reduction of chronic hyperglycaemia and attenuation of glucose toxicity, SGLT-2 inhibitors can improve both insulin secretion by beta cells and peripheraltissue insulin sensitivity. In the case of canagliflozin, because of low-potency SGLT1 inhibition, a non-renal (intestinal) effect may also be considered, which may contribute to better control of postprandial hyperglycaemia, although this contribution remains to be better analyzed in humans. Second, chronic glucose loss most probably leads to compensatory mechanisms. One of them, although not well evidenced in humans, might involve an increase in energy intake, an effect that may limit weight loss in the long run. Another could be an increase in endogenous glucose production, most probably driven by increased glucagon secretion, which may somewhat attenuate the glucoselowering effect. Nevertheless, despite these compensatory mechanisms and most probably because of the positive effects of the reduction in glucotoxicity, SGLT-2 inhibitors exert clinically relevant glucose-lowering activity while promoting weight loss, a unique dual effect among oral antidiabetic agents. Furthermore, the combination of SGLT-2 inhibitors with other drugs that either have anorectic effects (such as incretin-based therapies) or reduce hepatic glucose output (like metformin) and, thus, may dampen these two compensatory mechanisms appears appealing for the management of type 2 diabetes mellitus." @default.
• W1993014774 created "2016-06-24" @default.
• W1993014774 creator A5039563874 @default.
• W1993014774 creator A5062140559 @default.
• W1993014774 date "2014-12-01" @default.
• W1993014774 modified "2023-10-16" @default.
• W1993014774 title "Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence" @default.
• W1993014774 cites W1523363225 @default.
• W1993014774 cites W1973038508 @default.
• W1993014774 cites W1979377480 @default.
• W1993014774 cites W1983085727 @default.
• W1993014774 cites W1990411608 @default.
• W1993014774 cites W2013892321 @default.
• W1993014774 cites W2021240626 @default.
• W1993014774 cites W2030815088 @default.
• W1993014774 cites W2038270027 @default.
• W1993014774 cites W2044904729 @default.
• W1993014774 cites W2048870206 @default.
• W1993014774 cites W2050647266 @default.
• W1993014774 cites W2052976889 @default.
• W1993014774 cites W2065399738 @default.
• W1993014774 cites W2068171948 @default.
• W1993014774 cites W2071477116 @default.
• W1993014774 cites W2075627118 @default.
• W1993014774 cites W2077519024 @default.
• W1993014774 cites W2077636750 @default.
• W1993014774 cites W2082515526 @default.
• W1993014774 cites W2090133572 @default.
• W1993014774 cites W2096329362 @default.
• W1993014774 cites W2102348011 @default.
• W1993014774 cites W2105660444 @default.
• W1993014774 cites W2108816189 @default.
• W1993014774 cites W2109728760 @default.
• W1993014774 cites W2111155556 @default.
• W1993014774 cites W2130570549 @default.
• W1993014774 cites W2131135469 @default.
• W1993014774 cites W2148958160 @default.
• W1993014774 cites W2156066074 @default.
• W1993014774 cites W2157405334 @default.
• W1993014774 cites W2159883745 @default.
• W1993014774 cites W2166613497 @default.
• W1993014774 cites W2167245776 @default.
• W1993014774 cites W2168926920 @default.
• W1993014774 cites W2169248481 @default.
• W1993014774 cites W2170695489 @default.
• W1993014774 cites W2171786511 @default.
• W1993014774 cites W4212888272 @default.
• W1993014774 cites W4234712705 @default.
• W1993014774 doi "https://doi.org/10.1016/s1262-3636(14)72689-8" @default.
• W1993014774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25554070" @default.
• W1993014774 hasPublicationYear "2014" @default.
• W1993014774 type Work @default.
• W1993014774 sameAs 1993014774 @default.
• W1993014774 citedByCount "84" @default.
• W1993014774 countsByYear W19930147742014 @default.
• W1993014774 countsByYear W19930147742015 @default.
• W1993014774 countsByYear W19930147742016 @default.
• W1993014774 countsByYear W19930147742017 @default.
• W1993014774 countsByYear W19930147742018 @default.
• W1993014774 countsByYear W19930147742019 @default.
• W1993014774 countsByYear W19930147742020 @default.
• W1993014774 countsByYear W19930147742021 @default.
• W1993014774 countsByYear W19930147742022 @default.
• W1993014774 countsByYear W19930147742023 @default.
• W1993014774 crossrefType "journal-article" @default.
• W1993014774 hasAuthorship W1993014774A5039563874 @default.
• W1993014774 hasAuthorship W1993014774A5062140559 @default.
• W1993014774 hasConcept C126322002 @default.
• W1993014774 hasConcept C134018914 @default.
• W1993014774 hasConcept C2775887513 @default.
• W1993014774 hasConcept C2776453732 @default.
• W1993014774 hasConcept C2777180221 @default.
• W1993014774 hasConcept C2777422806 @default.
• W1993014774 hasConcept C2777451236 @default.
• W1993014774 hasConcept C2778199505 @default.
• W1993014774 hasConcept C2778881409 @default.
• W1993014774 hasConcept C2779306644 @default.
• W1993014774 hasConcept C2780323712 @default.
• W1993014774 hasConcept C2781214132 @default.
• W1993014774 hasConcept C511355011 @default.
• W1993014774 hasConcept C544821477 @default.
• W1993014774 hasConcept C555293320 @default.
• W1993014774 hasConcept C71924100 @default.
• W1993014774 hasConcept C90466245 @default.
• W1993014774 hasConcept C98274493 @default.
• W1993014774 hasConceptScore W1993014774C126322002 @default.
• W1993014774 hasConceptScore W1993014774C134018914 @default.
• W1993014774 hasConceptScore W1993014774C2775887513 @default.
• W1993014774 hasConceptScore W1993014774C2776453732 @default.
• W1993014774 hasConceptScore W1993014774C2777180221 @default.
• W1993014774 hasConceptScore W1993014774C2777422806 @default.
• W1993014774 hasConceptScore W1993014774C2777451236 @default.
• W1993014774 hasConceptScore W1993014774C2778199505 @default.
• W1993014774 hasConceptScore W1993014774C2778881409 @default.
• W1993014774 hasConceptScore W1993014774C2779306644 @default.
• W1993014774 hasConceptScore W1993014774C2780323712 @default.
• W1993014774 hasConceptScore W1993014774C2781214132 @default.
• W1993014774 hasConceptScore W1993014774C511355011 @default.

• next